Eisai To Establish U.K. Facility To Take Drugs From R&D To Market
This article was originally published in PharmAsia News
Eisai is opening a facility in the United Kingdom to take drugs from research through marketing, its first production base in Europe. The $165 million site is intended to more than double the company's drug researchers, to 60, and focus on developing drugs to treat mental ailments such as dementia. In a change from outsourcing its work to Europe, Eisai has decided to use a U.K. location to do research and develop, produce drugs and market them. Eisai expects to begin packaging drugs in the current fiscal year and produce pills and powders in fiscal 2010 with a capacity of producing 400 million pills a year. (Click here for more - a subscription may be required
You may also be interested in...
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.